Trial Profile
A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Dec 2013
Price :
$35
*
At a glance
- Drugs Obatoclax (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Feb 2013 New source identified and integrated (Mayo Clinic; 07-008520).